Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Posaconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 19/20 | 0.78 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.78 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.78 |
| ▸ | CYP8B1 | Q9UNU6 | 3/20 | 0.78 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.78 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.78 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.78 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 0.75 |
| ▸ | MAPT | P10636 | 3/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.75 |
| ▸ | FYN | P06241 | 2/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.75 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Posaconazole SCHEMBL20703831 | 0.95 | CYP3A4 (0.70) | CYP3A4ABCG2CYP19A1ABCB11CYP8B1 | |
| Posaconazole SCHEMBL4726547 | 0.91 | CYP3A4 (0.71) | CYP3A4ABCG2CYP19A1ABCB11CYP8B1 | |
| Itraconazole SCHEMBL8849763 | 0.90 | CYP3A4 (0.90) | CYP3A4ABCG2CYP19A1ABCB11CYP8B1 | |
| Posaconazole SCHEMBL18857056 | 0.88 | CYP3A4 (1.00) | CYP3A4ABCG2CYP19A1ABCB11CYP8B1 | |
| Posaconazole SCHEMBL20930912 | 0.88 | CYP3A4 (1.00) | CYP3A4ABCG2CYP19A1ABCB11CYP8B1 | |
| Posaconazole SCHEMBL23871970 | 0.88 | CYP3A4 (1.00) | CYP3A4ABCG2CYP19A1ABCB11CYP8B1 | |
| Posaconazole SCHEMBL13575780 | 0.88 | CYP3A4 (1.00) | CYP3A4ABCG2CYP19A1ABCB11CYP8B1 | |
| Posaconazole SCHEMBL1455343 | 0.88 | CYP3A4 (1.00) | CYP3A4ABCG2CYP19A1ABCB11CYP8B1 | |
| Posaconazole SCHEMBL6946672 | 0.88 | CYP3A4 (1.00) | CYP3A4ABCG2CYP19A1ABCB11CYP8B1 | |
| Posaconazole SCHEMBL15948109 | 0.88 | CYP3A4 (1.00) | CYP3A4ABCG2CYP19A1ABCB11CYP8B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088443-A1 | NOVEL CRYSTALLINE FORMS OF CONAZOLES AND METHODS OF MAKING AND USING THE SAME | REMENAR JULIUS | 2009-04-02 | — | — | US | disclosed |
| EP-1511490-A4 | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED PROCESSES, PHARMACEUTICAL COMPOSITIONS AND METHODS | TRANSFORM PHARMACEUTICALS INC (US) | 2009-03-11 | — | — | EP | disclosed |
| US-7446107-B2 | Crystalline forms of conazoles and methods of making and using the same | TRANSFORM PHARMACEUTICALS, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| WO-2008020830-A1 | METHOD OF TREATING AN ASPERGILLUS OR CRYPTOCOCCUS INFECTION BY ADMINISTERING AMBRUTICIN VS-3, VS-4, OR VS-5 | KOSAN BIOSCIENCES INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1718640-A4 | NOVEL CRYSTALLINE FORMS OF CONAZOLES AND METHODS OF MAKING AND USING THE SAME | TRANSFORM PHARMACEUTICALS INC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070293674-A1 | Novel Saperconazole Crystalline Forms and Related Processes, Pharmaceutical Compositions and Methods | TRANSFORM PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1831204-A2 | AMBRUTICIN VS COMPOUNDS | Kosan Biosciences, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070015823-A1 | Ambruticin VS compounds | KOSAN BIOSCIENCES INCORPORATED | 2007-01-18 | — | — | US | disclosed |
| EP-1742941-A1 | NOVEL SAPERCONAZOLE CRYSTALLINE FORMS AND RELATED PROCESSES, PHARMACEUTICAL COMPOSITIONS AND METHODS | Transform Pharmaceuticals, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1718640-A1 | NOVEL CRYSTALLINE FORMS OF CONAZOLES AND METHODS OF MAKING AND USING THE SAME | Transform Pharmaceuticals, Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| US-7078526-B2 | CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods | TRANSFORM PHARMACEUTICALS, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| WO-2006066147-A2 | AMBRUTICIN VS COMPOUNDS | KOSAN BIOSCIENCES INCORPORATED (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2005118577-A1 | NOVEL SAPERCONAZOLE CRYSTALLINE FORMS AND RELATED PROCESSES, PHARMACEUTICAL COMPOSITIONS AND METHODS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005092884-A1 | NOVEL CRYSTALLINE FORMS OF CONAZOLES AND METHODS OF MAKING AND USING THE SAME | TRANSFORM PHARMACEUTICALS, INC. (US) | 2005-10-06 | — | — | WO | disclosed |
| US-20050070551-A1 | Novel crystalline forms of conazoles and methods of making and using the same | TRANSFORM PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| EP-1511490-A2 | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED PROCESSES, PHARMACEUTICAL COMPOSITIONS AND METHODS | Transform Pharmaceuticals, Inc. (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040019211-A1 | Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-01-29 | — | — | US | disclosed |
| WO-2003101392-A2 | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED PROCESSES, PHARMACEUTICAL COMPOSITIONS AND METHODS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015823-A1 | Ambruticin VS compounds | ERG28, O60361, CYP51A1 | CYP3A4 551/4885ABCG2 2322/4885CYP19A1 891/4885 |
| US-20050070551-A1 | Novel crystalline forms of conazoles and methods of making and using the same | CYP51A1, CYP3A5, ERG28 | CYP3A4 10/4885ABCG2 115/4885CYP19A1 1315/4885 |
| US-20070293674-A1 | Novel Saperconazole Crystalline Forms and Related Processes, Pharmaceutical Compositions and Methods | CYP51A1, CYP3A5, CYP3A43 | CYP3A4 4/4885ABCG2 87/4885CYP19A1 520/4885 |
| US-20090088443-A1 | NOVEL CRYSTALLINE FORMS OF CONAZOLES AND METHODS OF MAKING AND USING THE SAME | CYP51A1, CYP3A5, ERG28 | CYP3A4 10/4885ABCG2 115/4885CYP19A1 1315/4885 |
| US-20040019211-A1 | Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods | CYP51A1, CYP3A5, CYP3A43 | CYP3A4 6/4885ABCG2 80/4885CYP19A1 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.